Skip to main content
Erschienen in: Hepatology International 5/2023

26.04.2023 | Original Article

Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure

verfasst von: Serami Murakami, Michio Imamura, Takuro Uchida, Yosuke Suehiro, Maiko Namba, Yasutoshi Fujii, Shinsuke Uchikawa, Yuji Teraoka, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Nelson C. Hayes, Masataka Tsuge, Hiroshi Aikata, Masahiro Ohira, Hideki Ohdan, Shiro Oka

Erschienen in: Hepatology International | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Aim

Heavy alcohol consumption is the most common etiology of acute-on-chronic liver failure (ACLF) in Japan. In some patients, ACLF is associated with a fatal outcome in less than 6 months. We evaluated the prognosis of patients with alcohol-related ACLF in our cohort and explored the prognostic factors.

Methods

Forty-six patients with alcoholic liver cirrhosis who fulfilled the Japanese diagnostic criteria for ACLF, including those classified as extended and/or probable, were enrolled in this study. Serum concentrations of inflammatory cytokines (interleukin [IL]-1β, IL-6, IL-8, IL-10, IL-12p70 and TNFα) were measured. We assessed prognosis and identified factors associated with survival.

Results

During the median 33-day observation period, 19 patients died, and 3 patients underwent living donor liver transplantation. Cumulative survival rates of patients treated without liver transplantation were 69, 48, 41, and 36% at 1, 3, 6, and 12 months, respectively. Eighteen of the 19 deceased patients died within 6 months after ACLF diagnosis. Serum concentrations of inflammatory cytokines were significantly elevated, and patients who underwent liver transplantation or who died within 6 months after admission had significantly higher serum IL-6 levels than the survival group. Multivariate analysis identified IL-6 > 23.3 pg/mL at admission and model for end-stage liver disease (MELD) score ≥ 25 on day 4 of admission as significant independent factors for mortality within 6 months.

Conclusion

Serum IL-6 level and Day-4 MELD were prognostic factors for alcohol-related ACLF. Early liver transplantation is a potential treatment option for patients whose prognosis is expected to be poor.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014;61:1038–1047CrossRefPubMed Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014;61:1038–1047CrossRefPubMed
2.
Zurück zum Zitat Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144(7):1426–1437CrossRefPubMed Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144(7):1426–1437CrossRefPubMed
3.
Zurück zum Zitat Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) 2014. Hepatol Int 2014;8:453–71CrossRefPubMed Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) 2014. Hepatol Int 2014;8:453–71CrossRefPubMed
4.
Zurück zum Zitat Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut BMJ 2017;66:541–553CrossRef Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut BMJ 2017;66:541–553CrossRef
5.
Zurück zum Zitat Zhang Q, Li Y, Han T, Nie CY, Cai JJ, Liu H, et al. Comparison of current diagnostic criteria for acute-on-chronic liver failure. PLoS One 2015;10(3):e0122158CrossRefPubMedPubMedCentral Zhang Q, Li Y, Han T, Nie CY, Cai JJ, Liu H, et al. Comparison of current diagnostic criteria for acute-on-chronic liver failure. PLoS One 2015;10(3):e0122158CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Nakayama N, Uemura H, Uchida Y, Tomiya T, Ido A, Inoue K, et al. A multicenter pilot survey to clarify the clinical features of patients with acute-on-chronic liver failure in Japan. Hepatol Res 2018;48:303–312CrossRefPubMed Nakayama N, Uemura H, Uchida Y, Tomiya T, Ido A, Inoue K, et al. A multicenter pilot survey to clarify the clinical features of patients with acute-on-chronic liver failure in Japan. Hepatol Res 2018;48:303–312CrossRefPubMed
7.
Zurück zum Zitat Khanam A, Kottilil S. Acute-on-chronic liver failure: pathophysiological mechanisms and management. Front Med (Lausanne) 2021;8:752875CrossRefPubMed Khanam A, Kottilil S. Acute-on-chronic liver failure: pathophysiological mechanisms and management. Front Med (Lausanne) 2021;8:752875CrossRefPubMed
9.
Zurück zum Zitat Marroni CA, de Fleck Medeiros A, Fernandes SA, Galant LH, Mucenic M, de Mattos Meine MH, et al. Liver transplantation and alcoholic liver disease: history, controversies, and considerations. World J Gastroenterol 2018;24:2785–2805CrossRefPubMedPubMedCentral Marroni CA, de Fleck Medeiros A, Fernandes SA, Galant LH, Mucenic M, de Mattos Meine MH, et al. Liver transplantation and alcoholic liver disease: history, controversies, and considerations. World J Gastroenterol 2018;24:2785–2805CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Im GY, Cameron AM, Lucey MR. Liver transplantation for alcoholic hepatitis. J Hepatol 2019;70:328–334CrossRefPubMed Im GY, Cameron AM, Lucey MR. Liver transplantation for alcoholic hepatitis. J Hepatol 2019;70:328–334CrossRefPubMed
11.
Zurück zum Zitat Mochida S, Nakayama N, Ido A, Inoue K, Genda T, Takikawa Y, et al. Proposed diagnostic criteria for acute-on-chronic liver failure in Japan. Hepatol Res 2018;48:219–224CrossRefPubMed Mochida S, Nakayama N, Ido A, Inoue K, Genda T, Takikawa Y, et al. Proposed diagnostic criteria for acute-on-chronic liver failure in Japan. Hepatol Res 2018;48:219–224CrossRefPubMed
12.
Zurück zum Zitat Mochida S, Nakayama N, Terai S, Yoshiji H, Shimizu M, Ido A, et al. Diagnostic criteria for acute-on-chronic liver failure and related disease conditions in Japan. Hepatol Res 2022;52:417–421CrossRefPubMed Mochida S, Nakayama N, Terai S, Yoshiji H, Shimizu M, Ido A, et al. Diagnostic criteria for acute-on-chronic liver failure and related disease conditions in Japan. Hepatol Res 2022;52:417–421CrossRefPubMed
13.
Zurück zum Zitat Cl J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 2016;64(4):1249–1264CrossRef Cl J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 2016;64(4):1249–1264CrossRef
14.
Zurück zum Zitat Zhou C, Zhang N, He TT, Wang Y, Wang LF, Sun YQ, et al. High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol 2020;26:4479–4488CrossRefPubMedPubMedCentral Zhou C, Zhang N, He TT, Wang Y, Wang LF, Sun YQ, et al. High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol 2020;26:4479–4488CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Padia G, Mahajan B, Kumar A, Sonika U, Dahale AS, Sachdeva S, et al. Cystatin C and interleukin-6 for prognosticating patients with acute decompensation of cirrhosis. JGH Open 2021;5:459–464CrossRefPubMedPubMedCentral Padia G, Mahajan B, Kumar A, Sonika U, Dahale AS, Sachdeva S, et al. Cystatin C and interleukin-6 for prognosticating patients with acute decompensation of cirrhosis. JGH Open 2021;5:459–464CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Agbim U, Sharma A, Maliakkal B, Karri S, Yazawa M, Goldkamp W, et al. Outcomes of liver transplant recipients with acute-on-chronic liver failure based on EASL-CLIF consortium definition: a single-center study. Transplant Direct 2020;6(4):e544CrossRefPubMedPubMedCentral Agbim U, Sharma A, Maliakkal B, Karri S, Yazawa M, Goldkamp W, et al. Outcomes of liver transplant recipients with acute-on-chronic liver failure based on EASL-CLIF consortium definition: a single-center study. Transplant Direct 2020;6(4):e544CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Marot A, Dubois M, Trépo E, Moreno C, Deltenre P. Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis. PLoS One 2018;13(1):e0190823CrossRefPubMedPubMedCentral Marot A, Dubois M, Trépo E, Moreno C, Deltenre P. Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis. PLoS One 2018;13(1):e0190823CrossRefPubMedPubMedCentral
18.
19.
Zurück zum Zitat Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365:1790–1800CrossRefPubMed Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011;365:1790–1800CrossRefPubMed
20.
Zurück zum Zitat Cai YJ, Dong JJ, Dong JZ, Chen Y, Lin Z, Song M, et al. A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure. Aliment Pharmacol Ther 2017;45:1413–1426CrossRefPubMed Cai YJ, Dong JJ, Dong JZ, Chen Y, Lin Z, Song M, et al. A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure. Aliment Pharmacol Ther 2017;45:1413–1426CrossRefPubMed
21.
Zurück zum Zitat Wu W, Yan H, Zhao H, Sun W, Yang Q, Sheng J, et al. Characteristics of systemic inflammation in hepatitis B-precipitated ACLF: differentiate it from No-ACLF. Liver Int 2018;38:248–257CrossRefPubMed Wu W, Yan H, Zhao H, Sun W, Yang Q, Sheng J, et al. Characteristics of systemic inflammation in hepatitis B-precipitated ACLF: differentiate it from No-ACLF. Liver Int 2018;38:248–257CrossRefPubMed
22.
Zurück zum Zitat Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Crit Care 2012;16:R227CrossRefPubMedPubMedCentral Jalan R, Stadlbauer V, Sen S, Cheshire L, Chang YM, Mookerjee RP. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Crit Care 2012;16:R227CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62:243–252CrossRefPubMed Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015;62:243–252CrossRefPubMed
24.
Zurück zum Zitat Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 2015;63:1272–1284CrossRefPubMed Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 2015;63:1272–1284CrossRefPubMed
25.
Zurück zum Zitat Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–454CrossRefPubMed Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–454CrossRefPubMed
26.
Zurück zum Zitat Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol 2016;64:1403–1415CrossRefPubMed Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol 2016;64:1403–1415CrossRefPubMed
27.
Zurück zum Zitat Xiang X, Feng D, Hwang S, Ren T, Wang X, Trojnar E, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. J Hepatol 2020;72:736–745CrossRefPubMed Xiang X, Feng D, Hwang S, Ren T, Wang X, Trojnar E, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. J Hepatol 2020;72:736–745CrossRefPubMed
28.
Zurück zum Zitat Mayr U, Lukas M, Elnegouly M, Vogt C, Bauer U, Ulrich J, et al. Ascitic interleukin 6 is associated with poor outcome and spontaneous bacterial peritonitis: a validation in critically ill patients with decompensated cirrhosis. J Clin Med 2020;9:1–15CrossRef Mayr U, Lukas M, Elnegouly M, Vogt C, Bauer U, Ulrich J, et al. Ascitic interleukin 6 is associated with poor outcome and spontaneous bacterial peritonitis: a validation in critically ill patients with decompensated cirrhosis. J Clin Med 2020;9:1–15CrossRef
Metadaten
Titel
Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure
verfasst von
Serami Murakami
Michio Imamura
Takuro Uchida
Yosuke Suehiro
Maiko Namba
Yasutoshi Fujii
Shinsuke Uchikawa
Yuji Teraoka
Hatsue Fujino
Atsushi Ono
Takashi Nakahara
Eisuke Murakami
Wataru Okamoto
Masami Yamauchi
Tomokazu Kawaoka
Daiki Miki
Nelson C. Hayes
Masataka Tsuge
Hiroshi Aikata
Masahiro Ohira
Hideki Ohdan
Shiro Oka
Publikationsdatum
26.04.2023
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 5/2023
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10532-x

Weitere Artikel der Ausgabe 5/2023

Hepatology International 5/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.